XZXu Zheng

Xu Zheng

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Xu Zheng has a total of 28 co-authors. Here are the top co-authors by number of shared publications:

  • Christina Cho

    Department of Immunobiology, Yale School of Medicine, New Haven, Connecticut, USA

    1 shared publication
  • Gangxiong Huang

    Tcelltech Biological Science and Technology, Fuzhou, China

    1 shared publication
  • Gen-Shu Wang

    The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, People’s Republic of China

    1 shared publication
  • Guosheng Wang

    Department of Rheumatology and Immunology The First Affiliated Hospital of USTC University of Science and Technology of China Hefei Anhui China ustc.edu.cn

    1 shared publication
  • Hui Chu

    Department of Rheumatology and Immunology The First Affiliated Hospital of USTC University of Science and Technology of China Hefei Anhui China ustc.edu.cn

    1 shared publication
  • Hui Li

    Department of Hepatic Surgery and Liver transplantation Center of the Third Affiliated Hospital, Organ Transplantation Institute, Sun Yat-sen University, Organ Transplantation Research Center of Guangdong Province, Guangzhou, Guangdong 510630, China

    1 shared publication

Latest Publications

  • Open Access

    Ablation of T cell–associated PD-1H enhances functionality and promotes adoptive immunotherapy

    by Li Hu, Ling Chen, Zexiu Xiao, Xu Zheng, Yuangui Chen, Na Xian, Christina Cho, Liqun Luo, Gangxiong Huang, Lieping Chen

    Programmed death-1 homolog (PD-1H) is a coinhibitory molecule that negatively regulates T cell–mediated immune responses. In this study, we determined whether ablation of T cell–associated PD-1H could enhance adoptive T cell therapy in experimental tumor models. The expression of PD-1H is upregulated in activated and tumor-infiltrating CD8 + T cells. Activated CD8 + T cells from PD-1H–deficient (PD-1H–KO) mice exhibited increased cell proliferation, cytokine production, and antitumor activity in vitro. Adoptive transfer of PD-1H–KO CD8 + T cells resulted in the regression of established syngeneic mouse tumors. Similar results were obtained when PD-1H was ablated in T cells by CRISPR/Cas9-mediated gene silencing. Furthermore, ablation of PD-1H in CAR-T cells significantly improved their antitumor activity against human xenografts in vivo. Our results indicate that T cell–associated PD-1H could suppress immunity in the tumor microenvironment and that targeting PD-1H may improve T cell adoptive immunotherapy.


  • Open Access

    B7‐H4 Inhibits the Development of Primary Sjögren’s Syndrome by Regulating Treg Differentiation in NOD/Ltj Mice

    by Xu Zheng, Qikai Wang, Xiang Yuan, Yingbo Zhou, Hui Chu, Guosheng Wang, Xiangpei Li, Yiping Wang, Li Wei, Li Wang, et al.

    Background . This study is aimed at exploring the role of B7‐H4 in the pathogenesis of primary Sjögren’s syndrome (pSS) in NOD/Ltj mouse. Methods . B7‐H4 expression in salivary glands was examined by IHC, and lymphocyte infiltration was showed by H&E. Next, anti‐B7‐H4 mAb or immunoglobulin isotype was injected into NOD/Ltj mice. Cytokine levels were measured by quantitative RT‐PCR, and immunoglobulins were measured by ELISA. T cell subsets were analyzed by flow cytometry. Last, we treated NOD/Ltj mice with B7‐H4Ig and control Ig. CD4+Foxp3+ T cells were assessed by immunohistochemistry. Two‐tailed Student’s t ‐tests were used to detect the statistical difference in various measures between the two groups. Results . B7‐H4 expression was remarkably reduced in salivary glands of NOD/Ltj mice at 15 weeks compared with the NOD/Ltj mice at 8 weeks. Anti‐B7‐H4 mAb treatment increased lymphocyte infiltration in salivary glands. Inflammatory cytokines including IL‐12, IL‐18, IL‐1 α , TNF‐ α , IFN‐ α , and BAFF were upregulated markedly in anti‐B7‐H4 mAb‐treated mice compared to IgG isotype‐treated mice. Flow cytometry analysis showed that anti‐B7‐H4 mAb‐treated mice had lower levels of CD4+Foxp3+/CD4+ T cells in spleen. Moreover, Foxp3 mRNA levels of salivary glands were diminished in anti‐B7‐H4 mAb‐treated mice. Flow cytometry analysis showed that anti‐B7‐H4 mAb inhibited CD4+Foxp3+/CD4+ T cell production, while B7‐H4Ig would promote naïve CD4+ T into Treg differentiation. Administration with B7‐H4Ig displayed significantly decreased lymphocyte infiltration in salivary glands and low levels of total IgM and IgG in serum. Analysis of inflammatory cytokines in salivary glands after B7‐H4Ig treatment revealed that the mRNA levels of IL‐12, IL‐6, IL‐18, IL‐1 α , TNF‐ α , and IFN‐ α were significantly downregulated in B7‐H4Ig‐treated mice compared to control Ig treatment. B7‐H4Ig‐treated mice had significantly higher levels of CD4+Foxp3+/CD4+ T cells in spleen. IHC in salivary gland revealed that CD4+Foxp3+ T cells of B7‐H4Ig treatment mouse were more than control Ig treatment. Conclusions . Our findings implicate that B7‐H4 has a protective role for salivary gland epithelial cells (SGECs) and therapeutic potential in the treatment of pSS.


  • Open Access

    Mesenchymal Stem Cells Ameliorate Hepatic Ischemia/Reperfusion Injury via Inhibition of Neutrophil Recruitment

    by Shihui Li, Xu Zheng, Hui Li, Jun Zheng, Xiaolong Chen, Wei Liu, Yan Tai, Yingcai Zhang, Genshu Wang, Yang Yang

    Ischemia/reperfusion injury (IRI) remains a major problem in organ transplantation, which represents the main cause of graft dysfunction posttransplantation. Hepatic IRI is characterized by an excessive inflammatory response within the liver. Mesenchymal stem cells (MSCs) have been shown to be immunomodulatory cells and have the therapeutic action on IRI in several organs. However, the mechanism of regulatory effect of MSCs on IRI remains unclear. In the present study, we examined the impact of MSCs on hepatic inflammatory response such as neutrophil influx and liver damage in a rat model of 70% hepatic IRI. Treatment with MSCs protected rat against hepatic IRI, with significantly decreased serum levels of liver enzymes, attenuated hepatic neutrophil infiltration, reduced expression of apoptosis-associated proteins, and ameliorated liver pathological injury. MSCs also significantly enhanced the intracellular activation of p38 MAPK phosphorylation, which led to decreased expression of CXCR2 on the surface of neutrophils. In addition, MSCs significantly diminished neutrophil chemoattractant CXCL2 production by inhibiting NF-κB p65 phosphorylation in macrophages. These results demonstrate that MSCs significantly ameliorate hepatic IRI predominantly through its inhibitory effect on hepatic neutrophil migration and infiltration.